ALX Oncology Holdings Inc. (ALXO) 10-Year Financial Performance & Capital Metrics

ALXO • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.Show more

Revenue $0
EBITDA -$142M +16.4%
Net Income -$135M +16.1%
EPS (Diluted) -2.58 +31.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -88.91% -25.3%
ROIC -71.82% -15.2%
Debt/Equity 0.15 +64.8%
Interest Coverage -82.40 +24.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 94 (top 6%)
✓Trading at only 0.6x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 21.4% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM28.55%

EPS CAGR

10Y-

5Y-

3Y-

TTM31.88%

ROCE

10Y Avg-91.31%

5Y Avg-47.16%

3Y Avg-64.91%

Latest-84.85%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	2.07M	4.8M	1.18M	0	0	0	0
Revenue Growth %	-	1.32%	-0.75%	-1%	-	-	-
Cost of Goods Sold+	1.88M	4.36M	1.07M	0	0	0	0
COGS % of Revenue	0.91%	0.91%	0.91%	-	-	-	-
Gross Profit+	187K	436K	107K	0	0	0	0
Gross Margin %	0.09%	0.09%	0.09%	-	-	-	-
Gross Profit Growth %	-	1.33%	-0.75%	-1%	-	-	-
Operating Expenses+	13.87M	19.62M	43.77M	83.56M	127.44M	170.28M	142.47M
OpEx % of Revenue	6.71%	4.09%	37.03%	-	-	-	-
Selling, General & Admin	2.6M	3.31M	14.81M	23.39M	29.04M	28.48M	26.09M
SG&A % of Revenue	1.26%	0.69%	12.53%	-	-	-	-
Research & Development	11.27M	16.31M	28.96M	60.17M	98.4M	141.79M	116.37M
R&D % of Revenue	5.45%	3.4%	24.5%	-	-	-	-
Other Operating Expenses	-2K	0	0	0	0	0	0
Operating Income+	-13.68M	-19.18M	-43.66M	-83.56M	-127.44M	-170.28M	-142.47M
Operating Margin %	-6.62%	-4%	-36.94%	-	-	-	-
Operating Income Growth %	-	-0.4%	-1.28%	-0.91%	-0.53%	-0.34%	0.16%
EBITDA+	-13.25M	-18.75M	-43.46M	-83.5M	-127.09M	-169.44M	-141.59M
EBITDA Margin %	-6.41%	-3.91%	-36.77%	-	-	-	-
EBITDA Growth %	-	-0.42%	-1.32%	-0.92%	-0.52%	-0.33%	0.16%
D&A (Non-Cash Add-back)	431K	429K	202K	51K	342K	836K	872K
EBIT	-13.69M	-19.19M	-43.66M	-83.47M	-123.18M	-159.24M	-133.12M
Net Interest Income+	0	-21K	-811K	-12.91K	4.04M	9.08M	7.64M
Interest Income	0	0	0	91	4.28M	10.65M	9.37M
Interest Expense	0	21K	811K	13K	238K	1.56M	1.73M
Other Income/Expense	-2K	-26K	-1.84M	71K	4.02M	9.47M	7.62M
Pretax Income+	-13.69M	-19.21M	-45.5M	-83.48M	-123.42M	-160.81M	-134.85M
Pretax Margin %	-6.62%	-4.01%	-38.49%	-	-	-	-
Income Tax+	45K	34K	241K	-21K	64K	0	0
Effective Tax Rate %	1%	1%	1.01%	1%	1%	1%	1%
Net Income+	-13.73M	-19.24M	-45.74M	-83.46M	-123.48M	-160.81M	-134.85M
Net Margin %	-6.64%	-4.01%	-38.7%	-	-	-	-
Net Income Growth %	-	-0.4%	-1.38%	-0.82%	-0.48%	-0.3%	0.16%
Net Income (Continuing)	-13.73M	-19.24M	-45.74M	-83.46M	-123.48M	-160.81M	-134.85M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-0.63	-0.88	-1.28	-2.07	-3.03	-3.74	-2.58
EPS Growth %	-	-0.4%	-0.45%	-0.62%	-0.46%	-0.23%	0.31%
EPS (Basic)	-0.63	-0.88	-1.28	-2.07	-3.03	-3.74	-2.58
Diluted Shares Outstanding	21.95M	21.95M	39.84M	40.31M	40.7M	42.99M	52.17M
Basic Shares Outstanding	21.95M	21.95M	39.84M	40.31M	40.7M	42.99M	52.17M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	10.21M	9.81M	435.99M	367.02M	270.97M	188.66M	134.35M
Cash & Short-Term Investments	8.26M	9.02M	434.22M	363.67M	266.21M	182.74M	127.76M
Cash Only	8.26M	9.02M	434.22M	363.67M	48.82M	22.41M	17.57M
Short-Term Investments	0	0	0	0	217.38M	160.33M	110.19M
Accounts Receivable	932K	536K	0	0	0	0	892K
Days Sales Outstanding	164.58	40.79	-	-	-	-	-
Inventory	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	4.76M	5.92M	5.7M
Total Non-Current Assets+	956K	867K	62K	13.16M	35.52M	53.89M	13.42M
Property, Plant & Equipment	956K	860K	52K	3.47M	9.81M	10.84M	9.63M
Fixed Asset Turnover	2.16x	5.58x	22.73x	-	-	-	-
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	16.7M	35.41M	3.52M
Other Non-Current Assets	0	7K	10K	9.69M	9.01M	7.64M	267K
Total Assets+	11.16M	10.68M	436.05M	380.18M	306.49M	242.55M	147.78M
Asset Turnover	0.19x	0.45x	0.00x	-	-	-	-
Asset Growth %	-	-0.04%	39.84%	-0.13%	-0.19%	-0.21%	-0.39%
Total Current Liabilities+	1.87M	4.98M	6.2M	15.29M	28.32M	36M	18.5M
Accounts Payable	697K	3.75M	4K	3.76M	8.07M	8.59M	4.5M
Days Payables Outstanding	135.32	313.77	1.36	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	435K
Deferred Revenue (Current)	0	0	0	0	0	0	0
Other Current Liabilities	369K	1.06M	2.13M	3.53M	4.72M	6.7M	5.97M
Current Ratio	5.45x	1.97x	70.28x	24.00x	9.57x	5.24x	7.26x
Quick Ratio	5.45x	1.97x	70.28x	24.00x	9.57x	5.24x	7.26x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	136K	5.97M	5K	1.84M	14.7M	16.84M	15.66M
Long-Term Debt	0	5.42M	0	0	9.39M	9.64M	9.47M
Capital Lease Obligations	0	0	0	0	0	5.98M	5.16M
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	412K	5K	1.84M	5.31M	1.22M	1.03M
Total Liabilities	2.01M	10.95M	6.21M	17.13M	43.02M	52.84M	34.16M
Total Debt+	0	5.42M	0	742K	10.43M	17.2M	16.98M
Net Debt	-8.26M	-3.6M	-434.22M	-362.93M	-38.39M	-5.21M	-589K
Debt / Equity	-	-	-	0.00x	0.04x	0.09x	0.15x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-	-913.48x	-53.84x	-6427.31x	-535.45x	-108.80x	-82.40x
Total Equity+	9.15M	-276K	429.85M	363.05M	263.46M	189.71M	113.62M
Equity Growth %	-	-1.03%	1558.41%	-0.16%	-0.27%	-0.28%	-0.4%
Book Value per Share	0.42	-0.01	10.79	9.01	6.47	4.41	2.18
Total Shareholders' Equity	9.15M	-276K	429.85M	363.05M	263.46M	189.71M	113.62M
Common Stock	3K	3K	40K	41K	41K	50K	53K
Retained Earnings	-53.54M	-72.78M	-118.52M	-201.99M	-325.47M	-486.27M	-621.12M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	-1.02M	0	0	0	-845K	256K	275K
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-13.19M	-14.25M	-38.29M	-68.1M	-89.22M	-130.36M	-121.91M
Operating CF Margin %	-6.38%	-2.97%	-32.39%	-	-	-	-
Operating CF Growth %	-	-0.08%	-1.69%	-0.78%	-0.31%	-0.46%	0.06%
Net Income	-13.73M	-19.24M	-45.74M	-83.46M	-123.48M	-160.81M	-134.85M
Depreciation & Amortization	431K	429K	202K	51K	342K	836K	872K
Stock-Based Compensation	269K	297K	5.44M	13.91M	23.84M	26.27M	27.09M
Deferred Taxes	0	0	0	0	0	0	0
Other Non-Cash Items	2.33M	11K	1.57M	5.42M	228K	-4.96M	-2.6M
Working Capital Changes	-159K	4.26M	247K	-4.03M	9.85M	8.3M	-12.43M
Change in Receivables	-932K	396K	536K	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	-269K	2.98M	-3.74M	3.29M	4.51M	458K	-4.02M
Cash from Investing+	-653K	-353K	610K	-4.92M	-235.42M	44.66M	86.26M
Capital Expenditures	-653K	-353K	-31K	-4.92M	-1.43M	-1.27M	-447K
CapEx % of Revenue	0.32%	0.07%	0.03%	-	-	-	-
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	641K	0	-233.99K	0	0
Cash from Financing+	1K	15.36M	462.88M	2.47M	9.86M	59.29M	30.82M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	7K	10K	-10.05M	0	-655K	792K	0
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-13.84M	-14.6M	-38.32M	-73.02M	-90.65M	-131.64M	-122.36M
FCF Margin %	-6.7%	-3.04%	-32.42%	-	-	-	-
FCF Growth %	-	-0.05%	-1.62%	-0.91%	-0.24%	-0.45%	0.07%
FCF per Share	-0.63	-0.67	-0.96	-1.81	-2.23	-3.06	-2.35
FCF Conversion (FCF/Net Income)	0.96x	0.74x	0.84x	0.82x	0.72x	0.81x	0.90x
Interest Paid	0	0	427K	11K	0	0	0
Taxes Paid	0	0	47K	274K	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-149.98%	-433.45%	-21.3%	-21.05%	-39.42%	-70.97%	-88.91%
Return on Invested Capital (ROIC)	-1149.27%	-	-	-50537.3%	-84.88%	-62.36%	-71.82%
Gross Margin	9.05%	9.09%	9.05%	-	-	-	-
Net Margin	-664.3%	-401.23%	-3869.71%	-	-	-	-
Debt / Equity	-	-	-	0.00x	0.04x	0.09x	0.15x
Interest Coverage	-	-913.48x	-53.84x	-6427.31x	-535.45x	-108.80x	-82.40x
FCF Conversion	0.96x	0.74x	0.84x	0.82x	0.72x	0.81x	0.90x
Revenue Growth	-	132.03%	-75.35%	-100%	-	-	-

Frequently Asked Questions

Growth & Financials

ALX Oncology Holdings Inc. (ALXO) grew revenue by 0.0% over the past year. Growth has been modest.

ALX Oncology Holdings Inc. (ALXO) reported a net loss of $108.0M for fiscal year 2024.

Dividend & Returns

ALX Oncology Holdings Inc. (ALXO) has a return on equity (ROE) of -88.9%. Negative ROE indicates the company is unprofitable.

ALX Oncology Holdings Inc. (ALXO) had negative free cash flow of $97.4M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

ALX Oncology Holdings Inc. (ALXO) 10-Year Financial Performance & Capital Metrics

ALXO • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $0
EBITDA -$142M +16.4%
Net Income -$135M +16.1%
EPS (Diluted) -2.58 +31.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -88.91% -25.3%
ROIC -71.82% -15.2%
Debt/Equity 0.15 +64.8%
Interest Coverage -82.40 +24.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 94 (top 6%)
✓Trading at only 0.6x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 21.4% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM28.55%

EPS CAGR

10Y-

5Y-

3Y-

TTM31.88%

ROCE

10Y Avg-91.31%

5Y Avg-47.16%

3Y Avg-64.91%

Latest-84.85%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	2.07M	4.8M	1.18M	0	0	0	0
Revenue Growth %	-	1.32%	-0.75%	-1%	-	-	-
Cost of Goods Sold+	1.88M	4.36M	1.07M	0	0	0	0
COGS % of Revenue	0.91%	0.91%	0.91%	-	-	-	-
Gross Profit+	187K	436K	107K	0	0	0	0
Gross Margin %	0.09%	0.09%	0.09%	-	-	-	-
Gross Profit Growth %	-	1.33%	-0.75%	-1%	-	-	-
Operating Expenses+	13.87M	19.62M	43.77M	83.56M	127.44M	170.28M	142.47M
OpEx % of Revenue	6.71%	4.09%	37.03%	-	-	-	-
Selling, General & Admin	2.6M	3.31M	14.81M	23.39M	29.04M	28.48M	26.09M
SG&A % of Revenue	1.26%	0.69%	12.53%	-	-	-	-
Research & Development	11.27M	16.31M	28.96M	60.17M	98.4M	141.79M	116.37M
R&D % of Revenue	5.45%	3.4%	24.5%	-	-	-	-
Other Operating Expenses	-2K	0	0	0	0	0	0
Operating Income+	-13.68M	-19.18M	-43.66M	-83.56M	-127.44M	-170.28M	-142.47M
Operating Margin %	-6.62%	-4%	-36.94%	-	-	-	-
Operating Income Growth %	-	-0.4%	-1.28%	-0.91%	-0.53%	-0.34%	0.16%
EBITDA+	-13.25M	-18.75M	-43.46M	-83.5M	-127.09M	-169.44M	-141.59M
EBITDA Margin %	-6.41%	-3.91%	-36.77%	-	-	-	-
EBITDA Growth %	-	-0.42%	-1.32%	-0.92%	-0.52%	-0.33%	0.16%
D&A (Non-Cash Add-back)	431K	429K	202K	51K	342K	836K	872K
EBIT	-13.69M	-19.19M	-43.66M	-83.47M	-123.18M	-159.24M	-133.12M
Net Interest Income+	0	-21K	-811K	-12.91K	4.04M	9.08M	7.64M
Interest Income	0	0	0	91	4.28M	10.65M	9.37M
Interest Expense	0	21K	811K	13K	238K	1.56M	1.73M
Other Income/Expense	-2K	-26K	-1.84M	71K	4.02M	9.47M	7.62M
Pretax Income+	-13.69M	-19.21M	-45.5M	-83.48M	-123.42M	-160.81M	-134.85M
Pretax Margin %	-6.62%	-4.01%	-38.49%	-	-	-	-
Income Tax+	45K	34K	241K	-21K	64K	0	0
Effective Tax Rate %	1%	1%	1.01%	1%	1%	1%	1%
Net Income+	-13.73M	-19.24M	-45.74M	-83.46M	-123.48M	-160.81M	-134.85M
Net Margin %	-6.64%	-4.01%	-38.7%	-	-	-	-
Net Income Growth %	-	-0.4%	-1.38%	-0.82%	-0.48%	-0.3%	0.16%
Net Income (Continuing)	-13.73M	-19.24M	-45.74M	-83.46M	-123.48M	-160.81M	-134.85M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-0.63	-0.88	-1.28	-2.07	-3.03	-3.74	-2.58
EPS Growth %	-	-0.4%	-0.45%	-0.62%	-0.46%	-0.23%	0.31%
EPS (Basic)	-0.63	-0.88	-1.28	-2.07	-3.03	-3.74	-2.58
Diluted Shares Outstanding	21.95M	21.95M	39.84M	40.31M	40.7M	42.99M	52.17M
Basic Shares Outstanding	21.95M	21.95M	39.84M	40.31M	40.7M	42.99M	52.17M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	10.21M	9.81M	435.99M	367.02M	270.97M	188.66M	134.35M
Cash & Short-Term Investments	8.26M	9.02M	434.22M	363.67M	266.21M	182.74M	127.76M
Cash Only	8.26M	9.02M	434.22M	363.67M	48.82M	22.41M	17.57M
Short-Term Investments	0	0	0	0	217.38M	160.33M	110.19M
Accounts Receivable	932K	536K	0	0	0	0	892K
Days Sales Outstanding	164.58	40.79	-	-	-	-	-
Inventory	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	4.76M	5.92M	5.7M
Total Non-Current Assets+	956K	867K	62K	13.16M	35.52M	53.89M	13.42M
Property, Plant & Equipment	956K	860K	52K	3.47M	9.81M	10.84M	9.63M
Fixed Asset Turnover	2.16x	5.58x	22.73x	-	-	-	-
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	16.7M	35.41M	3.52M
Other Non-Current Assets	0	7K	10K	9.69M	9.01M	7.64M	267K
Total Assets+	11.16M	10.68M	436.05M	380.18M	306.49M	242.55M	147.78M
Asset Turnover	0.19x	0.45x	0.00x	-	-	-	-
Asset Growth %	-	-0.04%	39.84%	-0.13%	-0.19%	-0.21%	-0.39%
Total Current Liabilities+	1.87M	4.98M	6.2M	15.29M	28.32M	36M	18.5M
Accounts Payable	697K	3.75M	4K	3.76M	8.07M	8.59M	4.5M
Days Payables Outstanding	135.32	313.77	1.36	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	435K
Deferred Revenue (Current)	0	0	0	0	0	0	0
Other Current Liabilities	369K	1.06M	2.13M	3.53M	4.72M	6.7M	5.97M
Current Ratio	5.45x	1.97x	70.28x	24.00x	9.57x	5.24x	7.26x
Quick Ratio	5.45x	1.97x	70.28x	24.00x	9.57x	5.24x	7.26x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	136K	5.97M	5K	1.84M	14.7M	16.84M	15.66M
Long-Term Debt	0	5.42M	0	0	9.39M	9.64M	9.47M
Capital Lease Obligations	0	0	0	0	0	5.98M	5.16M
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	412K	5K	1.84M	5.31M	1.22M	1.03M
Total Liabilities	2.01M	10.95M	6.21M	17.13M	43.02M	52.84M	34.16M
Total Debt+	0	5.42M	0	742K	10.43M	17.2M	16.98M
Net Debt	-8.26M	-3.6M	-434.22M	-362.93M	-38.39M	-5.21M	-589K
Debt / Equity	-	-	-	0.00x	0.04x	0.09x	0.15x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-	-913.48x	-53.84x	-6427.31x	-535.45x	-108.80x	-82.40x
Total Equity+	9.15M	-276K	429.85M	363.05M	263.46M	189.71M	113.62M
Equity Growth %	-	-1.03%	1558.41%	-0.16%	-0.27%	-0.28%	-0.4%
Book Value per Share	0.42	-0.01	10.79	9.01	6.47	4.41	2.18
Total Shareholders' Equity	9.15M	-276K	429.85M	363.05M	263.46M	189.71M	113.62M
Common Stock	3K	3K	40K	41K	41K	50K	53K
Retained Earnings	-53.54M	-72.78M	-118.52M	-201.99M	-325.47M	-486.27M	-621.12M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	-1.02M	0	0	0	-845K	256K	275K
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-13.19M	-14.25M	-38.29M	-68.1M	-89.22M	-130.36M	-121.91M
Operating CF Margin %	-6.38%	-2.97%	-32.39%	-	-	-	-
Operating CF Growth %	-	-0.08%	-1.69%	-0.78%	-0.31%	-0.46%	0.06%
Net Income	-13.73M	-19.24M	-45.74M	-83.46M	-123.48M	-160.81M	-134.85M
Depreciation & Amortization	431K	429K	202K	51K	342K	836K	872K
Stock-Based Compensation	269K	297K	5.44M	13.91M	23.84M	26.27M	27.09M
Deferred Taxes	0	0	0	0	0	0	0
Other Non-Cash Items	2.33M	11K	1.57M	5.42M	228K	-4.96M	-2.6M
Working Capital Changes	-159K	4.26M	247K	-4.03M	9.85M	8.3M	-12.43M
Change in Receivables	-932K	396K	536K	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	-269K	2.98M	-3.74M	3.29M	4.51M	458K	-4.02M
Cash from Investing+	-653K	-353K	610K	-4.92M	-235.42M	44.66M	86.26M
Capital Expenditures	-653K	-353K	-31K	-4.92M	-1.43M	-1.27M	-447K
CapEx % of Revenue	0.32%	0.07%	0.03%	-	-	-	-
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	641K	0	-233.99K	0	0
Cash from Financing+	1K	15.36M	462.88M	2.47M	9.86M	59.29M	30.82M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	7K	10K	-10.05M	0	-655K	792K	0
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-13.84M	-14.6M	-38.32M	-73.02M	-90.65M	-131.64M	-122.36M
FCF Margin %	-6.7%	-3.04%	-32.42%	-	-	-	-
FCF Growth %	-	-0.05%	-1.62%	-0.91%	-0.24%	-0.45%	0.07%
FCF per Share	-0.63	-0.67	-0.96	-1.81	-2.23	-3.06	-2.35
FCF Conversion (FCF/Net Income)	0.96x	0.74x	0.84x	0.82x	0.72x	0.81x	0.90x
Interest Paid	0	0	427K	11K	0	0	0
Taxes Paid	0	0	47K	274K	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-149.98%	-433.45%	-21.3%	-21.05%	-39.42%	-70.97%	-88.91%
Return on Invested Capital (ROIC)	-1149.27%	-	-	-50537.3%	-84.88%	-62.36%	-71.82%
Gross Margin	9.05%	9.09%	9.05%	-	-	-	-
Net Margin	-664.3%	-401.23%	-3869.71%	-	-	-	-
Debt / Equity	-	-	-	0.00x	0.04x	0.09x	0.15x
Interest Coverage	-	-913.48x	-53.84x	-6427.31x	-535.45x	-108.80x	-82.40x
FCF Conversion	0.96x	0.74x	0.84x	0.82x	0.72x	0.81x	0.90x
Revenue Growth	-	132.03%	-75.35%	-100%	-	-	-

Frequently Asked Questions

Growth & Financials

ALX Oncology Holdings Inc. (ALXO) grew revenue by 0.0% over the past year. Growth has been modest.

ALX Oncology Holdings Inc. (ALXO) reported a net loss of $108.0M for fiscal year 2024.

Dividend & Returns

ALX Oncology Holdings Inc. (ALXO) has a return on equity (ROE) of -88.9%. Negative ROE indicates the company is unprofitable.

ALX Oncology Holdings Inc. (ALXO) had negative free cash flow of $97.4M in fiscal year 2024, likely due to heavy capital investments.